SUNNYVALE, Calif.--Hyseq, a genomics company here, has signed its first pharmacogenomics agreement to work with the University of California, San Francisco, to study genes that may play important roles in the development of arteriosclerotic heart disease, stroke, diabetes, hypertension, and related metabolic disorders. In terms of the amount of sequence data generated, Hyseq claims the collaboration will be the largest ever in the cardiovascular field.